PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Articles with Puma Biotechnology
Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology
Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations
Can Puma Biotechnology Inc (PBYI) Stock Rise to the Top of Healthcare Sector Tuesday?
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology Reports Third Quarter 2022 Financial Results | Business Wire
